Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):310-3. doi: 10.1097/QAI.0000000000000964.

Abstract

Viral load (VL) rebound timing and set point were analyzed in 235 participants undergoing analytic treatment interruption (ATI) in 6 AIDS Clinical Trials Group studies. There was no significant association between rebound timing and ATI VL set point for those who rebounded ≤12 weeks. VL set points were lower in participants with rebound >12 weeks (P < 0.001) and participants treated during early infection (P < 0.001). Pre-antiretroviral therapy VL correlated with set point, though 68% of participants had a set point lower than pre-antiretroviral therapy VL. These results illustrate complex relationships between post-ATI virologic outcomes and the potential presence of biological factors mediating rebound timing and set point.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / therapeutic use
  • Clinical Trials as Topic*
  • Datasets as Topic
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology*
  • HIV-1 / drug effects*
  • HIV-1 / isolation & purification
  • Humans
  • Leukocytes, Mononuclear / virology
  • Male
  • RNA, Viral / analysis
  • Time Factors
  • Treatment Outcome
  • Viral Load / drug effects*
  • Withholding Treatment

Substances

  • Anti-HIV Agents
  • RNA, Viral